Literature DB >> 31079286

Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model.

Yong Yan1, Yanhua Sha2, Xianzhang Huang2, Wei Yuan1, Fan Wu1, Jinsong Hong1, Shaomei Fang1, Bo Huang1, Cheng Hu3, Bailin Wang4, Xueli Zhang5.   

Abstract

BACKGROUND: Roux-en-Y gastric bypass (RYGB) is an effective surgical treatment for type 2 diabetes mellitus (T2DM). The present study aimed to investigate the effects of RYGB on glucose homeostasis, lipid metabolism, and liver morphological adaption, as well as the changes in bile acids signaling and expression of its target regulatory factors involved in gluconeogenesis, lipogenesis, and fatty acid β oxidation.
METHODS: Twenty adult male T2DM rats induced by high-fat diet and a low dose of streptozotocin were randomly divided into sham and RYGB groups. The parameters of body weight, food intake, glucose tolerance, insulin sensitivity, serum lipid profiles, and bile acids level were assessed to evaluate metabolic changes. Liver sections were stained with hematoxylin-eosin (H&E) and oil red O to assess lipid accumulation. The mRNA and protein expression levels of farnesoid X receptor (FXR), small heterodimer partner (SHP), key regulatory factors of gluconeogenesis, lipogenesis, and fatty acid β oxidation (phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase), sterol regulatory element-binding protein-1c (SREBP-1c), peroxisome proliferator-activated receptor-α (PPAR-α)) were determined through RT-PCR and Western blotting, respectively.
RESULTS: RYGB induced significant improvements in glucose tolerance and insulin sensitivity, along with weight loss and decreased food intake. RYGB also decreased serum TG, FFAs, and increased bile acids levels. The lipid droplets in the liver were significantly decreased after RYGB. The RYGB group exhibited downregulated mRNA and protein expression levels of PEPCK, G6Pase, and SREBP-1c and upregulated expression of FXR, SHP, and PPAR-α in the liver.
CONCLUSIONS: RYGB ameliorates glucose and lipid metabolism accompanied by weight loss and calorie restriction. The liver exhibited a marked improvement in lipid accumulation after RYGB. The bile acids level, FXR, and its target transcriptional factor SHP expression were elevated. Meanwhile, our study demonstrated that the increased bile acids-FXR signaling, followed by the reduced hepatic gluconeogenesis, lipogenesis, and increased fatty acid β oxidation may contribute to improved metabolic conditions after RYGB.

Entities:  

Keywords:  Bariatric surgery; Bile acids; Farnesoid X receptor; Gluconeogenesis; Glucose homeostasis; High-fat diet; Lipid profiles; Lipogenesis; Roux-en-Y gastric bypass; Small heterodimer partner; Streptozotocin; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2019        PMID: 31079286     DOI: 10.1007/s11695-019-03918-0

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  59 in total

Review 1.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.

Authors:  Jay D Horton; Joseph L Goldstein; Michael S Brown
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.

Authors:  Yanqiao Zhang; Florence Ying Lee; Gabriel Barrera; Hans Lee; Charisse Vales; Frank J Gonzalez; Timothy M Willson; Peter A Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-12       Impact factor: 11.205

3.  Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters.

Authors:  Stefan Bilz; Varman Samuel; Katsutaro Morino; David Savage; Cheol Soo Choi; Gerald I Shulman
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-11-15       Impact factor: 4.310

4.  Farnesoid X receptor activation mediates head-to-tail chromatin looping in the Nr0b2 gene encoding small heterodimer partner.

Authors:  Guodong Li; Ann M Thomas; Steven N Hart; Xiaobo Zhong; Dequan Wu; Grace L Guo
Journal:  Mol Endocrinol       Date:  2010-05-05

Review 5.  Bariatric surgery for type 2 diabetes.

Authors:  John B Dixon; Carel W le Roux; Francesco Rubino; Paul Zimmet
Journal:  Lancet       Date:  2012-06-09       Impact factor: 79.321

6.  Bariatric surgery: an IDF statement for obese Type 2 diabetes.

Authors:  J B Dixon; P Zimmet; K G Alberti; F Rubino
Journal:  Surg Obes Relat Dis       Date:  2011-06-01       Impact factor: 4.734

7.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.

Authors:  Mitsuhiro Watanabe; Sander M Houten; Li Wang; Antonio Moschetta; David J Mangelsdorf; Richard A Heyman; David D Moore; Johan Auwerx
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

8.  Evolution of glycolipid profile after sleeve gastrectomy vs. Roux-en-Y gastric bypass: results of a prospective randomized clinical trial.

Authors:  Michel Vix; Michele Diana; Keng-Hao Liu; Antonio D'Urso; Didier Mutter; Hurng-Sheng Wu; Jacques Marescaux
Journal:  Obes Surg       Date:  2013-05       Impact factor: 4.129

9.  Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.

Authors:  Inés Pineda Torra; Thierry Claudel; Caroline Duval; Vladimir Kosykh; Jean-Charles Fruchart; Bart Staels
Journal:  Mol Endocrinol       Date:  2003-02

10.  Farnesoid X receptor is essential for normal glucose homeostasis.

Authors:  Ke Ma; Pradip K Saha; Lawrence Chan; David D Moore
Journal:  J Clin Invest       Date:  2006-03-23       Impact factor: 14.808

View more
  3 in total

1.  The Role of Bile Acid in Improving Glucose Tolerance of Non-Obese Diabetic Rats After Proximal Small Bowel Bypass.

Authors:  Zhihua Zheng; Qiang Pang; Xin Luo; Fang Tao; Jinyuan Duan; Jiaqing Cao
Journal:  Front Physiol       Date:  2022-06-16       Impact factor: 4.755

2.  Simulating the Post-gastric Bypass Intestinal Microenvironment Uncovers a Barrier-Stabilizing Role for FXR.

Authors:  Mohammed K Hankir; Theresa Langseder; Ezgi Eyluel Bankoglu; Yalda Ghoreishi; Ulrich Dischinger; Max Kurlbaum; Matthias Kroiss; Christoph Otto; Carel W le Roux; Tulika Arora; Florian Seyfried; Nicolas Schlegel
Journal:  iScience       Date:  2020-11-05

3.  Metabolomics analysis of stool in rats with type 2 diabetes mellitus after single-anastomosis duodenal-ileal bypass with sleeve gastrectomy.

Authors:  Lun Wang; Zeyu Wang; Yang Yu; Zhaoheng Ren; Yongheng Jia; Jinfa Wang; Shixing Li; Tao Jiang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-20       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.